Septerna, Inc. Increase (Decrease) in Contract with Customer, Liability
Septerna, Inc. (SEPN) reported Increase (Decrease) in Contract with Customer, Liability of -$27.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-10
- Septerna, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$11.55M.
- Septerna, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$16.24M.
- Septerna, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$14.06M.
- Septerna, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was $168.19M.
- Septerna, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was $0.00.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$11.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$27.79M 10-Q · filed 2026-08-10 | -$41.85M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2026-03-31 | -$16.24M 10-Q · filed 2026-05-11 | -$30.30M derived: sum of 2 quarters · filed 2026-05-11 | ||
| 2025-12-31 | -$14.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $168.19M 10-K · filed 2026-03-09 | ||
| 2025-09-30 | $182.25M 10-Q · filed 2025-11-10 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |